supported by the Shanghai Municipal Health Commission Young Foundation(No.20194Y0270);Science and Technology Commission of Shanghai Municipality(No.20ZR1448100).
Phosphodiesterase(PDE)inhibitors can improve sperm motility in patients with asthenozoospermia.However,the most commonly reported nonselective PDE inhibitor pentoxifylline and PDE5 inhibitor sildenafil have the disadv...
We aimed to determine whether combination of LIM-kinase 2 inhibitor(LIMK2i)and phosphodiesterase type-5 inhibitor(PDE5i)could restore erectile function through suppressing cavernous fibrosis and improving caver nous a...
The introduction of oral phosphodiesterase-5 inhibitors (PDE51s) in the late 1990s and early 2000s revolutionized the field of sexual medicine and PDE51s are currently first-line monotherapy for erectile dysfunction...
Aim: To study the effects of homocysteine and copper on type 5 phosphodiesterase (PDE5) expression in cavemosai vascular smooth muscle cells (CVSMCs) and to investigate superoxide (O2-) derived from nicotinamid...
Aim: To evaluate the efficacy and safety of SK3530, a newly developed type 5 phosphodiesterase inhibitor (PDE5I), in Korean men with erectile dysfunction (ED). Methods: A total of 119 patients were randomized at...
Aim: To test the hypothesis that sildenafil (50 mg nightly for one year) can improve spontaneous erectile function (EF) in men with mild-to-moderate arteriogenic erectile dysfunction (ED) responsive to erectoge...